<![CDATA[Bispecific Antibodies Are Advancing Into Earlier-Line Multiple Myeloma]]>

Summary

An oncologist comments that bispecific antibodies are expected to advance into the newly diagnosed multiple myeloma setting as a matter of time. This is a general market commentary without specific clinical data or regulatory catalysts.